GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Cefixime

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Suprax / Cefixime

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Suprax - product and source limitations

Conventional hemodialysis and peritoneal dialysis remove little cefixime. Check the exact formulation when a reduced dose is needed.

Before applying: Verify the current prescribing information for this presentation.

Also check: Suprax - product and source limitations

Historical source

Original GlobalRPh source

Choose a product and source Suprax | Product label Suprax | GlobalRPh RX passage All evidence
Product / population
Preserved GlobalRPh source, not a freshly verified product label
Renal measure
Use the method specified in the original source
Source revision
Historical source; revision not established here
Retrieved
2026-09-05 (not the revision date)

Historical source: not automatically current. Review current official labeling and separately attributed additions before use.

Source summary and narrative differ at exactly 20 and 60 mL/min. Both are retained; do not silently resolve the boundary.

Usual Dosing (Adults)

400 mg orally every 24 hours or 200 mg every 12 hours.

Renal Dosing

Source summary: CrCl >60 mL/min: 400 mg/day; 21 to 60: 300 mg/day; <=20: 200 mg/day.

Suprax may be administered in the presence of impaired renal function. Normal dose and schedule may be employed in patients with creatinine clearances of 60 mL/min or greater. Patients whose clearance is between 21 and 60 mL/min or who are on renal hemodialysis may be given 75% of the standard dosage at the standard dosing interval (300 mg daily). Patients whose clearance is <20 mL/min, or who are on continuous ambulatory peritoneal dialysis, may be given half the standard dosage (200 mg daily). Neither hemodialysis nor peritoneal dialysis removes significant amounts of the drug from the body.

Hemodialysis

See the renal dosing text above.

Source revision: Historical source; revision not established here | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://globalrph.com/renal/cefixime/

Scope: Preserved historical source; no fresh clinical approval GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v7.4

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Suprax - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 2, posted Dec 30, 2019

Renal measure: Creatinine clearance (CrCl), mL/min

Read this dated source finding
Rxlist

Suprax - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
See all retained evidence sources
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Suprax - labeled renal guidance

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Cefixime (Suprax), oral capsule

Renal method: Creatinine clearance (CrCl), mL/min
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Suprax - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Suprax - product and source limitations

Conventional hemodialysis and peritoneal dialysis remove little cefixime. Check the exact formulation when a reduced dose is needed.

How to use this: Verify the current prescribing information for this presentation.

Suprax - labeled renal guidanceSuprax - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeSuprax - labeled renal guidanceSuprax - selected RX renal passage
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

Source summary and narrative differ at exactly 20 and 60 mL/min. Both are retained; do not silently resolve the boundary.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/cefixime/

Usual Dosing (Adults)

400 mg orally every 24 hours or 200 mg every 12 hours.

GRPH-cefixime-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

Source summary: CrCl >60 mL/min: 400 mg/day; 21 to 60: 300 mg/day; <=20: 200 mg/day.

Suprax may be administered in the presence of impaired renal function. Normal dose and schedule may be employed in patients with creatinine clearances of 60 mL/min or greater. Patients whose clearance is between 21 and 60 mL/min or who are on renal hemodialysis may be given 75% of the standard dosage at the standard dosing interval (300 mg daily). Patients whose clearance is <20 mL/min, or who are on continuous ambulatory peritoneal dialysis, may be given half the standard dosage (200 mg daily). Neither hemodialysis nor peritoneal dialysis removes significant amounts of the drug from the body.

GRPH-cefixime-02 · Source section: Renal DosingRenal section finder

Hemodialysis

See the renal dosing text above.

GRPH-cefixime-03 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Suprax - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Cefixime (Suprax), oral capsule

Renal method: Creatinine clearance (CrCl), mL/min
Source date: DailyMed SPL version 2, posted Dec 30, 2019
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 2.3 Renal Impairment / 5.3 Dose Adjustment in Renal Impairment / 8.6 Renal Impairment

Use the usual adult dose and interval at CrCl 60 mL/min or greater. Below that value use the table for the specified presentation and suspension concentration. Conventional hemodialysis and peritoneal dialysis remove little cefixime. Check the exact formulation when a reduced dose is needed.

RDM74-suprax-official-1 · Source locator: Renal guidance: 2.3 Renal Impairment / 5.3 Dose Adjustment in Renal Impairment / 8.6 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=655a59ba-08e9-51d4-e053-2991aa0aef34
Retrieved
2026-11-07
Renal-function method
Creatinine clearance (CrCl), mL/min
Source date/version
DailyMed SPL version 2, posted Dec 30, 2019
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
b5f648257622b8bfb0659b4631f7f0a282ee0644e736ff1294e8995a65c76099
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Suprax - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Cefixime (Suprax), oral capsule

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror identifies 60 mL/min as the threshold for the usual adult schedule.

RDM74-suprax-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/suprax-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
271ae7bacb215f5c327c4d9e35db52e58fc49c7edaa65a17301b8ee0f2913b6f

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/cefixime/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
50d886b4260041097c8b490d18f9b4786de9b014a2ec839ed589678ce9c61ef1
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top